Search

Your search keyword '"Chiu, Hung‐Chih"' showing total 133 results
Start Over Author "Chiu, Hung‐Chih"
133 results on '"Chiu, Hung‐Chih"'

1. Precise application of topical tranexamic acid to enhance endoscopic hemostasis for peptic ulcer bleeding: a randomized controlled study (with video)

Author

Chiang, Hsueh-Chien, Chen, Po-Jun, Yang, Er-Hsiang, Hsieh, Ming-Tsung, Shih, I-Cheng, Cheng, Hsiu-Chi, Chang, Wei-Lun, Chen, Wei-Ying, Chiu, Hung-Chih, Kuo, Hsin-Yu, Tsai, Wei-Chu, Lo, Yi-Ning, Yang, Kai-Chun, Chiang, Chien-Ming, Chen, Wei-Chih, Huang, Kuan-Kai, Tseng, Hsu-Huan, Chen, Chiung-Yu, Lin, Xi-Zhang, and Chuang, Chiao-Hsiung

Published
2023
Full Text
View/download PDF

7. Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B

Author

Cheng, Pin‐Nan, primary, Feng, I‐Cher, additional, Chen, Jyh‐Jou, additional, Kuo, Hsing‐Tao, additional, Lee, Pei‐Lun, additional, Yu, Ming‐Lung, additional, Chiu, Yen‐Cheng, additional, Chiu, Hung‐Chih, additional, Chien, Shih‐Chieh, additional, Chen, Pei‐Jer, additional, and Liu, Chun‐Jen, additional

Published
2023
Full Text
View/download PDF

9. Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B.

Author

Cheng, Pin‐Nan, Feng, I‐Cher, Chen, Jyh‐Jou, Kuo, Hsing‐Tao, Lee, Pei‐Lun, Yu, Ming‐Lung, Chiu, Yen‐Cheng, Chiu, Hung‐Chih, Chien, Shih‐Chieh, Chen, Pei‐Jer, and Liu, Chun‐Jen

Subjects
CHRONIC hepatitis B, INSULIN aspart, BODY weight, LDL cholesterol, DISEASE risk factors, TENOFOVIR
Abstract

Summary: Background: Lipid‐lowering effect was observed during treatment with tenofovir disoproxil fumarate (TDF) for chronic hepatitis B (CHB). However, the metabolic features in patients switching from TDF to tenofovir alafenamide (TAF) remain unclear. Aims: To compare the impacts of switching from TDF to TAF or from entecavir to TAF on body weight and metabolic features in patients with CHB. Methods: This was a multi‐centre, prospective, observational study in patients with CHB on TDF or entecavir who switched to TAF. Baseline characteristics, lipid profile and sugar profile were determined. This study received IRB approval from each hospital. Results: We enrolled 177 patients on TDF (99) or entecavir (78) and followed them for 48 weeks after the switch to TAF. At baseline, TDF‐experienced patients had lower serum triglyceride, total cholesterol, high‐density lipoprotein (HDL) cholesterol and low‐density lipoprotein (LDL) cholesterol than entecavir‐experienced patients. The switch from TDF to TAF significantly increased body weight, triglyceride, total cholesterol, HDL, LDL, fasting glucose, glycaemic haemoglobin, insulin and insulin resistance. The switch from entecavir to TAF did not affect these measures. There was no significant difference in atherosclerotic cardiovascular disease risk scores between groups. Conclusions: The switch from TDF to TAF was associated with weight gain, derangements of lipid profile, and increased insulin resistance in patients with CHB. Long‐term effects on these metabolic features need further investigation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. 0484 The association between obstructive sleep apnea, energy balance and body composition: a clinical cohort

Author

Lee, Pei-Lin, primary, Lai, Shang-Ru, additional, Gooley, Joshua, additional, Feng, Hsin-Chun, additional, Chen, Shih-Kuo, additional, Chien, Meng-Yueh, additional, Lin, Ming-Tzer, additional, Chen, Yung-Hsuan, additional, Chiu, Hung-Chih, additional, Liu, Po-Kang, additional, Ku, Bo-Wen, additional, Chang, Chin-Hao, additional, Yang, Wei-Shiung, additional, and Yu, Chong-Jen, additional

Published
2023
Full Text
View/download PDF

15. Higher Risk of Tumor Recurrence in NASH-Related Hepatocellular Carcinoma Following Curative Resection

Author

Chien, Shih-Chieh, primary, Lin, Yih-Jyh, additional, Lee, Chun-Te, additional, Chiu, Yen-Cheng, additional, Chou, Tsung-Ching, additional, Chiu, Hung-Chih, additional, Tsai, Hung-Wen, additional, Su, Che-Min, additional, Yang, Tsung-Han, additional, Chiang, Hsueh-Chien, additional, Tsai, Wei-Chu, additional, Yang, Kai-Chun, additional, and Cheng, Pin-Nan, additional

Published
2022
Full Text
View/download PDF

27. Autophagy Drives Galectin-1 Secretion From Tumor-Associated Macrophages Facilitating Hepatocellular Carcinoma Progression

Author

Davuluri, Goutham Venkata Naga, primary, Chen, Chien-Chin, additional, Chiu, Yen-Cheng, additional, Tsai, Hung-Wen, additional, Chiu, Hung-Chih, additional, Chen, Yuh-Ling, additional, Tsai, Pei-Jane, additional, Kuo, Wan-Ting, additional, Tsao, Nina, additional, Lin, Yee-Shin, additional, and Chang, Chih-Peng, additional

Published
2021
Full Text
View/download PDF

37. Persistent augmentation of central arterial stiffness following viral clearance by direct‐acting antivirals in chronic hepatitis C.

Author

Chen, Ju‐Yi, Cheng, Pin‐Nan, Chiu, Yen‐Cheng, Chiu, Hung‐Chih, Tsai, Wei‐Chuan, and Tsai, Liang‐Miin

Subjects
CHRONIC hepatitis C, ARTERIAL diseases, ANTIVIRAL agents, HEPATITIS C, HEPATITIS C virus, BRACHIAL artery
Abstract

Chronic hepatitis C virus (HCV) infection is associated with risk of cardiovascular diseases. Although direct‐acting antivirals (DAA) result in rapid eradication of HCV, their long‐term impact on arterial stiffness remains unclear. This study aimed to evaluate changes in parameters of central arterial stiffness from pretreatment, through sustained virological response, to one year after viral clearance. Patients with chronic HCV receiving DAA treatment were enrolled prospectively. Medical history and comorbidities of all patients were collected. Lipid profiles, liver stiffness by transient elastography and central blood pressures using pulse wave analysis of the brachial artery by cuff sphygmomanometry were measured before treatment, at viral clearance and at one year following viral clearance. Augmentation index (AIx), a parameter of aortic stiffness, was calculated as the ratio of augmentation pressure to central pulse pressure. After DAA treatment, all included patients with chronic HCV (n = 102) had achieved viral clearance. Cholesterol, low‐density lipoprotein (LDL) and triglyceride/high‐density lipoprotein (TG/HDL) increased significantly at viral clearance and persisted at one year (all P <.001). AIx was also elevated significantly at viral clearance and persisted one year later (P <.001). Changes in AIx remained significant only in patients with increased values from baseline in either LDL (P <.01) or TG/HDL (P <.001). Central arterial stiffness and lipid profiles in patients with chronic HCV worsen immediately after viral eradication by DAA treatment and persist at one year. Worsening of lipid profiles after DAA treatment contributes to central arterial stiffness in this patient population and persists long term. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

38. Real‐world effectiveness and safety of ledipasvir/sofosbuvir for genotype 6 chronic hepatitis C patients in Taiwan.

Author

Chen, Jyh‐Jou, Lee, Pei‐Lun, Chiu, Hung‐Chih, Tung, Hung‐Da, Chiu, Yen‐Cheng, and Cheng, Pin‐Nan

Subjects
CHRONIC hepatitis C, GLYCOSYLATED hemoglobin, HEPATITIS C virus, ALANINE aminotransferase, GENOTYPES, HEPATITIS C
Abstract

Background and Aim: Infection with hepatitis C virus (HCV) genotype (GT) 6 is uncommon in Taiwan, and reports of ledipasvir/sofosbuvir (LDV/SOF) treatment for GT6 are few. This study evaluates the effectiveness and safety of LDV/SOF in treating chronic hepatitis C (CHC) patients with GT6 infection. Methods: CHC patients that were infected with GT6 and treated for 12 weeks with LDV/SOF at two hospitals were enrolled. All patients were followed for an additional 12 weeks after the completion of LDV/SOF treatment. Demographics, HCV viral load, lipid and sugar profiles, and adverse events were recorded and reviewed. Results: A total of 127 patients were enrolled. Cirrhosis was found in 68.2% of them. Sustained virological response (SVR), determined by per‐protocol analysis, was 97.6%. The SVR rates for cirrhosis versus non‐cirrhosis (96.5% vs 100%, P = 0.229) and low versus high viral load (cutoff value: 106 IU/mL; 100% vs 95.6%, P = 0.108) were similar. Following HCV clearance, significantly lower glycosylated hemoglobin was present both in patients with or without diabetes mellitus. Twenty‐three (18.1%) patients exhibited adverse events, and each adverse event presented with an incidence of 0.8% to 3.1%. Neuropsychiatric symptoms were the most common. During treatment, 18 patients (14.2%) had alanine aminotransferase elevations consistent with more than grade 1 abnormalities, and none had signs of decompensation. Renal function remained unchanged. Conclusion: The high SVR and excellent safety of LDV/SOF treatment for GT6 CHC patients suggest that LDV/SOF is a favorable option for treating GT6 CHC patients in Taiwan and Asia. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

42. Serial heart rhythm complexity changes in patients with anterior wall ST segment elevation myocardial infarction

Author

Chiu, Hung-Chih, primary, Ma, Hsi-Pin, additional, Lin, Chen, additional, Lo, Men-Tzung, additional, Lin, Lian-Yu, additional, Wu, Cho-Kai, additional, Chiang, Jiun-Yang, additional, Lee, Jen-Kuang, additional, Hung, Chi-Sheng, additional, Wang, Tzung-Dau, additional, Daisy Liu, Li-Yu, additional, Ho, Yi-Lwun, additional, Lin, Yen-Hung, additional, and Peng, Chung-Kang, additional

Published
2017
Full Text
View/download PDF

49. An implantable microsystem for studying the Parkinson's Disease

Author

Chen, Yung-Chan, primary, Lin, Yu-Po, additional, Hsieh, Tsui-Ling, additional, Yeh, Chun-Yi, additional, Huang, Pin-Yang, additional, Chiu, Hung-Chih, additional, Wang, Zong-Ye, additional, Hsu, Wen-Yang, additional, Huang, Po-Chiun, additional, Tang, Kea-Tiong, additional, Ma, Hsi-Pin, additional, and Chen, Hsin, additional

Published
2012
Full Text
View/download PDF

50. Reversibility of some oxidative stress markers in chronic hepatitis C patients after receiving direct-acting antiviral agents

Author

Cheng, Pin-Nan, Sun, Hung-Yu, Feng, I-Che, Wang, Sin-Tian, Chiu, Yen-Cheng, Chiu, Hung-Chih, Chien, Shih-Chieh, and Young, Kung-Chia

Abstract

Hepatitis C (HCV) is associated with extra-hepatic involvment, morbidity as well as metabolic changes. Whether these might be reversible if sustained virologic response (SVR) is achieved by direct-acting antiviral (DAA) therapy remains unknown.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results